You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药(02196.HK):9月25日复宏汉霖H股于港交所主板上市
格隆汇 09-25 16:48

格隆汇9月25日丨复星医药(02196.HK)公告,关于建议分拆上海复宏汉霖生物技术股份有限公司并于香港联合交易所有限公司主板独立上市的进展。

香港联交所已批准复宏汉霖H股股份在香港联交所主板上市及买卖。在全球发售完成后,(i)复宏汉霖于2019年9月25日在香港联交所主板上市,及(ii)复宏汉霖H股股份于2019年9月25日上午九点整在香港联交所主板开始买卖。复宏汉霖H股股份以每手100股为单位买卖,股份代号为2696。

复宏汉霖自集团(即公司及控股子公司/单位,下同)分拆并独立上市,有利于复宏汉霖实现进一步发展,并提升集团整体价值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account